In silico design Stable molecule Formulation development Market launch
FGF2 for cultivation media   FGF2-STAB®
(patent WO2017089016A1)
 

Global distribution agreement

Global license agreement

FGF2 for cosmetics   FGF2-STAB®
(patent WO2017089016A1)
  Licensing partners sought
FGF2 for veterinary medicine   FGF2-STAB®
(patent WO2017089016A1)
  Licensing partners sought
FGF2 for wound healing   FGF2-STAB®
(patent WO2017089016A1)
 

Preclinical testing stage

Licensing partners sought

FGF10 for cultivation media       Preparation for market entry
FGF10 for lung injury/disease treatment (ALI/ARDS)      

Preclinical testing stage

Licensing partners sought

FGF7 for cell cultivation media      

Test samples on request

Licensing partners sought

FGF18 for osteoarthritis treatment      

Test samples on request

Licensing partners sought

FGF20 for metabolic disease treatment (obesity and diabetes)      

Test samples on request

Licensing partners sought

FGF21 for neurodegenerative disease treatment (AD and PD)      

Test samples on request

Licensing partners sought

Other FGFs for cell culture and medical use FGFx                            (3 new molecules)      

 

Our molecules are being developed with a support of: